Table 3. Comparative efficacy of biological agents for induction and maintenance therapy for anti-TNF therapy-experienced subpopulation.

	Odds ratio (95% CrI)
Time point (Endpoint)	Vedolizumab vs. adalimumab	Vedolizumab vs. placebo	Adalimumab vs. placebo
Induction
Clinical response	1.74 (0.69–4.45)	2.51* (1.18–5.48)	1.43 (0.79–2.64)
Clinical remission	2.72 (0.43–23.79)	3.66 (0.87–27.98)	1.37 (0.47–4.03)
Mucosal healing	1.56 (0.57–4.22)	1.70 (0.80–3.81)	1.09 (0.60–2.10)
Maintenance
Durable clinical response	2.04 (0.44–9.01)	4.89* (1.74–15.89)	2.47 (0.90–6.99)
Clinical remission	3.40 (0.40–32.52)	12.14* (3.14–78.38)	3.60* (1.01–18.23)
Mucosal healing	6.72* (1.36–41.17)	9.09* (2.74–40.06)	1.36 (0.50–3.91)

CrI, credible interval; OR, odds ratio; TNF, tumour necrosis factor.

* = significant.